Literature DB >> 21166993

Microvascular thrombosis and CD40/CD40L signaling.

F N E Gavins1, G Li, J Russell, M Perretti, D N Granger.   

Abstract

BACKGROUND: Although inflammation and thrombosis are now recognized to be interdependent processes that activate and perpetuate each other, the signaling molecules that link these two processes remain poorly understood.
OBJECTIVES: The objective of this study was to assess the contribution of the CD40/CD40L signaling system to the enhanced microvascular thrombosis that accompanies two distinct experimental models of inflammation, that is, endotoxemia (lipopolysaccharide [LPS]) and dextran sodium sulfate (DSS)-induced colitis.
METHODS: Thrombosis was induced in cerebral (LPS model) and cremaster muscle (DSS model) arterioles and venules of wild-type (WT) mice and mice deficient in either CD40 (CD40(-/-)) or CD40L (CD40L(-/-)), using the light/dye (photoactivation) method. RESULTS AND
CONCLUSIONS: A comparison of thrombus formation between WT and mutant mice revealed a role for CD40 and/or CD40L in the inflammation-enhanced thrombosis responses in both of the cerebral and muscle vasculatures. However, the relative contributions of CD40 and its ligand to thrombus formation differed between vascular beds (brain vs. muscle) and vessel types (arterioles vs. venules). The protective effect of CD40L deficiency in cerebral arterioles exposed to LPS was significantly blunted by administration of soluble CD40L. These findings implicate CD40 and its ligand in the enhanced thrombus formation that is associated with acute and chronic inflammation.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21166993      PMCID: PMC3050075          DOI: 10.1111/j.1538-7836.2010.04176.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  26 in total

Review 1.  The CD40/CD40L costimulatory pathway in inflammatory bowel disease.

Authors:  S Danese; M Sans; C Fiocchi
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

2.  Differential role of von Willebrand factor and P-selectin on microvascular thrombosis in endotoxemia.

Authors:  Kavita N Patel; Said H Soubra; Ricardo V Bellera; Jing-Fei Dong; Colleen A McMullen; Alan R Burns; Rolando E Rumbaut
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-09-18       Impact factor: 8.311

Review 3.  The blood-brain barrier.

Authors:  M W Bradbury
Journal:  Exp Physiol       Date:  1993-07       Impact factor: 2.969

Review 4.  The blood-brain barrier: morphology, molecules, and neurothelin.

Authors:  B Schlosshauer
Journal:  Bioessays       Date:  1993-05       Impact factor: 4.345

5.  Hypercholesterolemia enhances thromboembolism in arterioles but not venules: complete reversal by L-arginine.

Authors:  Martijn A W Broeders; Geert Jan Tangelder; Dick W Slaaf; Robert S Reneman; Mirjam G A oude Egbrink
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

6.  Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice.

Authors:  U Schönbeck; G K Sukhova; K Shimizu; F Mach; P Libby
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

7.  Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease.

Authors:  Ioannis E Koutroubakis; Angeliki Theodoropoulou; Costas Xidakis; Aekaterini Sfiridaki; George Notas; George Kolios; Elias A Kouroumalis
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-11       Impact factor: 2.566

8.  Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.

Authors:  S Danese; J A Katz; S Saibeni; A Papa; A Gasbarrini; M Vecchi; C Fiocchi
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

9.  Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling.

Authors:  K S Srinivasa Prasad; Patrick Andre; Ming He; Ming Bao; Jeanne Manganello; David R Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

10.  Mouse cremaster venules are predisposed to light/dye-induced thrombosis independent of wall shear rate, CD18, ICAM-1, or P-selectin.

Authors:  Rolando E Rumbaut; Jaspreet Kaur Randhawa; C Wayne Smith; Alan R Burns
Journal:  Microcirculation       Date:  2004 Apr-May       Impact factor: 2.628

View more
  14 in total

Review 1.  Platelets: a critical link between inflammation and microvascular dysfunction.

Authors:  Karen Y Stokes; D Neil Granger
Journal:  J Physiol       Date:  2011-12-19       Impact factor: 5.182

2.  The isothiocyanate sulforaphane modulates platelet function and protects against cerebral thrombotic dysfunction.

Authors:  Scarlett Gillespie; Paul M Holloway; Felix Becker; Francesca Rauzi; Shantel A Vital; Kirk A Taylor; Karen Y Stokes; Michael Emerson; Felicity N E Gavins
Journal:  Br J Pharmacol       Date:  2018-07-03       Impact factor: 8.739

3.  Targeting AnxA1/Formyl Peptide Receptor 2 Pathway Affords Protection against Pathological Thrombo-Inflammation.

Authors:  Shantel A Vital; Elena Y Senchenkova; Junaid Ansari; Felicity N E Gavins
Journal:  Cells       Date:  2020-11-13       Impact factor: 6.600

Review 4.  Effects of packed red blood cell storage duration on post-transfusion clinical outcomes: a meta-analysis and systematic review.

Authors:  Monica Suet Ying Ng; Angela Suet Yeung Ng; Jessica Chan; John-Paul Tung; John Francis Fraser
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

Review 5.  ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on 'coronary microvascular dysfunction in cardiovascular disease'.

Authors:  Teresa Padro; Olivia Manfrini; Raffaele Bugiardini; John Canty; Edina Cenko; Giuseppe De Luca; Dirk J Duncker; Etto C Eringa; Akos Koller; Dimitris Tousoulis; Danijela Trifunovic; Marija Vavlukis; Cor de Wit; Lina Badimon
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

6.  CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.

Authors:  Katelyn T Byrne; Nathan H Leisenring; David L Bajor; Robert H Vonderheide
Journal:  J Immunol       Date:  2016-05-23       Impact factor: 5.422

7.  Testosterone-to-estradiol ratio and platelet thromboxane release in ischemic heart disease: the EVA project.

Authors:  V Raparelli; C Nocella; M Proietti; G F Romiti; B Corica; S Bartimoccia; L Stefanini; A Lenzi; N Viceconte; G Tanzilli; V Cammisotto; L Pilote; R Cangemi; S Basili; R Carnevale
Journal:  J Endocrinol Invest       Date:  2022-03-09       Impact factor: 5.467

8.  CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.

Authors:  Anthony Shock; Linda Burkly; Ian Wakefield; Christopher Peters; Ellen Garber; Janine Ferrant; Frederick R Taylor; Lihe Su; Yen-Ming Hsu; David Hutto; Ali Amirkhosravi; Todd Meyer; John Francis; Sarah Malcolm; Martyn Robinson; Derek Brown; Stevan Shaw; Roland Foulkes; Alastair Lawson; Olivier Harari; Timothy Bourne; Alison Maloney; Neil Weir
Journal:  Arthritis Res Ther       Date:  2015-09-03       Impact factor: 5.156

9.  PPARγ ligands decrease hydrostatic pressure-induced platelet aggregation and proinflammatory activity.

Authors:  Fang Rao; Ren-Qiang Yang; Xiao-Shu Chen; Jin-Song Xu; Hui-Min Fu; Hai Su; Ling Wang
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

Review 10.  CD40L and Its Receptors in Atherothrombosis-An Update.

Authors:  Nathaly Anto Michel; Andreas Zirlik; Dennis Wolf
Journal:  Front Cardiovasc Med       Date:  2017-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.